TABLE 1.
Demographic, clinical, and laboratory characteristics of enrolled adult patients at baseline
| Characteristica | Datab for patients (n) in: |
||
|---|---|---|---|
| Nevirapine arm (21) | Efavirenz arm (17) | Total (38) | |
| Age (yr) | 34 (24–48) | 33 (21–50) | 33 (21–50) |
| Male | 12 (57.1) | 10 (58.8) | 22 (57.9) |
| Wt (kg) | 52.6 (40.5–68.5) | 51.3 (39.1–72.3) | 51.9 (39.1–72.3) |
| BMI (kg/m2) | 19.1 (14.4–24.3) | 18.7 (16.7–20.0) | 18.9 (14.4–30.1) |
| Hemoglobin (g/dl) | 8.9 (7.0–10.5) | 9.3 (7.5–11.7) | 9.1 (7.0–11.7) |
| ALT (IU/liter) | 25.3 (7.7–124.2) | 32.3 (13.3–123.6) | 29.9 (7.7–124.2) |
| Total bilirubin (mg/dl) | 0.4 (0.2–2.2) | 0.5 (0.1–1.3) | 0.4 (0.1–2.2) |
| CD4 count (cells/mm3) | 108 (2–206) | 93 (18–214) | 104 (2–214) |
| Plasma HIV-1 RNA (log10 copies/ml) | 5.7 (4.2–7.0) | 5.4 (4.3–6.6) | 5.5 (4.2–7.0) |
| Active hepatitis B infection | 1/17 (5.9) | 4/17 (23.5) | 5/34 (14.7) |
| HCV infection | 0 (0.0) | 1 (5.9) | 1 (2.6) |
| Gastrointestinal symptoms | 1 (4.8) | 1 (5.9) | 2 (5.3) |
| Time between start of tuberculosis therapy and start of antiretroviral therapy (days) | 33 (28–40) | 33 (28–41) | 33 (28–41) |
| Pulmonary tuberculosis | 18 (85.7) | 10 (58.8) | 28 (73.7) |
| Pulmonary tuberculosis smear results | |||
| Positive | 7 (33.3) | 8 (47.0) | 15 (39.5) |
| Negative or missing results | 14 (66.7) | 9 (53.0) | 23 (60.5) |
| Cavitary disease | 1/18 (5.6) | 0/16 (0) | 1/34 (2.9) |
a
BMI, body mass index; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus.
b
Data are no. (%), median (range), or no. affected/no. tested (%).